OCULIS HOLDING AG(NASDAQ:OCS) stock Fundamental Analysis

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to OCS. OCS was compared to 198 industry peers in the Pharmaceuticals industry. While OCS seems to be doing ok healthwise, there are quite some concerns on its profitability. OCS does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

OCS had negative earnings in the past year.

OCS had a negative operating cash flow in the past year.

OCS had negative earnings in each of the past 5 years.

In the past 5 years OCS always reported negative operating cash flow.

1.2 Ratios

OCS has a Return On Assets of -71.27%. This is in the lower half of the industry: OCS underperforms 68.69% of its industry peers.

OCS's Return On Equity of -116.89% is on the low side compared to the rest of the industry. OCS is outperformed by 60.61% of its industry peers.

		Industry Rank	Sector Rank
ROA	-71.27%
ROE	-116.89%
ROIC	N/A

ROA(3y)-84.45%

ROA(5y)-75.22%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

OCS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

The number of shares outstanding for OCS has been increased compared to 1 year ago.

OCS has a worse debt/assets ratio than last year.

2.2 Solvency

An Altman-Z score of 8.44 indicates that OCS is not in any danger for bankruptcy at the moment.

Looking at the Altman-Z score, with a value of 8.44, OCS belongs to the top of the industry, outperforming 87.37% of the companies in the same industry.

A Debt/Equity ratio of 0.01 indicates that OCS is not too dependend on debt financing.

OCS has a Debt to Equity ratio of 0.01. This is comparable to the rest of the industry: OCS outperforms 59.09% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.01
Debt/FCF	N/A
Altman-Z	8.44

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

OCS has a Current Ratio of 2.37. This indicates that OCS is financially healthy and has no problem in meeting its short term obligations.

Looking at the Current ratio, with a value of 2.37, OCS is in line with its industry, outperforming 44.95% of the companies in the same industry.

A Quick Ratio of 2.37 indicates that OCS has no problem at all paying its short term obligations.

OCS's Quick ratio of 2.37 is in line compared to the rest of the industry. OCS outperforms 50.51% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	2.37
Quick Ratio	2.37

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

OCS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -40.25%.

EPS 1Y (TTM)-40.25%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-45.49%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%19.84%

3.2 Future

OCS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 23.51% yearly.

OCS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 200.76% yearly.

EPS Next Y9.64%

EPS Next 2Y-0.84%

EPS Next 3Y-11.08%

EPS Next 5Y23.51%

Revenue Next Year7.32%

Revenue Next 2Y365.64%

Revenue Next 3Y327.69%

Revenue Next 5Y200.76%

3.3 Evolution

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

OCS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year OCS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A cheap valuation may be justified as OCS's earnings are expected to decrease with -11.08% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-0.84%

EPS Next 3Y-11.08%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for OCS!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

OCULIS HOLDING AG

NASDAQ:OCS (5/14/2025, 8:00:02 PM)

17.28

-0.48 (-2.7%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)05-08 2025-05-08/amc

Earnings (Next)N/A N/A

Inst Owners25.52%

Inst Owner ChangeN/A

Ins Owners2.78%

Ins Owner ChangeN/A

Market Cap811.12M

Analysts88.33

Price Target32.79 (89.76%)

Short Float %0.03%

Short Ratio0.34

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)1

Avg EPS beat(2)-25.26%

Min EPS beat(2)-51.79%

Max EPS beat(2)1.26%

EPS beat(4)1

Avg EPS beat(4)-22.88%

Min EPS beat(4)-51.79%

Max EPS beat(4)1.26%

EPS beat(8)2

Avg EPS beat(8)-17.67%

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)0

Avg Revenue beat(2)-54.65%

Min Revenue beat(2)-98.55%

Max Revenue beat(2)-10.76%

Revenue beat(4)0

Avg Revenue beat(4)-32.6%

Min Revenue beat(4)-98.55%

Max Revenue beat(4)-6.41%

Revenue beat(8)3

Avg Revenue beat(8)23.33%

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)5.14%

PT rev (3m)5.97%

EPS NQ rev (1m)0%

EPS NQ rev (3m)12.79%

EPS NY rev (1m)0.53%

EPS NY rev (3m)1.39%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)9.7%

Revenue NY rev (1m)-4.92%

Revenue NY rev (3m)-87.3%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	9.31
P/tB	11.37
EV/EBITDA	N/A

EPS(TTM)-2.73

EYN/A

EPS(NY)-2.54

Fwd EYN/A

FCF(TTM)-1.21

FCFYN/A

OCF(TTM)-1.2

OCFYN/A

SpS0

BVpS1.86

TBVpS1.52

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-71.27%
ROE	-116.89%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-84.45%

ROA(5y)-75.22%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score4

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0.01
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	56.65%
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	2.37
Quick Ratio	2.37
Altman-Z	8.44

F-Score4

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)418.9%

Cap/Depr(5y)255.58%

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-40.25%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-45.49%

EPS Next Y9.64%

EPS Next 2Y-0.84%

EPS Next 3Y-11.08%

EPS Next 5Y23.51%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%19.84%

Revenue Next Year7.32%

Revenue Next 2Y365.64%

Revenue Next 3Y327.69%

Revenue Next 5Y200.76%

EBIT growth 1Y-59.66%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-27.42%

EBIT Next 3Y-23.81%

EBIT Next 5YN/A

FCF growth 1Y11.44%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y11.79%

OCF growth 3YN/A

OCF growth 5YN/A

OCULIS HOLDING AG (OCS) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens